ETBI - Eastgate Biotech Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0090
+0.0006 (+7.14%)
At close: 1:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.0084
Open0.0084
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0084 - 0.0090
52 Week Range0.0021 - 0.0125
Volume416,390
Avg. Volume470,925
Market Cap18.97M
Beta (3Y Monthly)2.54
PE Ratio (TTM)N/A
EPS (TTM)-0.0070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer

    WEST CALDWELL, NJ and TORONTO, ON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today the appointment of distinguished executive Bill Abajian to lead the licensing and marketing phase of the company as Chief Operating Officer of the company, effective August 27, 2019. Mr. Abajian is a highly experienced, accomplished results-driven global senior management executive with a rare combination of a Long-View Strategist coupled with a Short-View Tactician who has the powerful understanding and commitment to get new business up and running successfully as well as Turning-Around Companies with his leadership in restoring or developing a culture for success.

  • GlobeNewswire

    EastGate Biotech Files Application to Initiate Phase III Clinical Trial for Insugin

    WEST CALDWELL, NJ and TORONTO, ON, June 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that it has filed an application with the Drug Regulatory Authority of Pakistan (DRAP) and Ministry of National Health Services to initiate a Phase III clinical study for Insugin.  EastGate recently completed a positive Phase II clinical trial of its innovative liquid insulin mouth rinse solution, Insugin, for Type 2 diabetes patients.  The Phase III trial design is consistent with the 90-day Phase II study that recently met its endpoints. The application requests the dosing of 200 Type 2 diabetic patients in order to achieve statistically significant results for regulatory approval of Insugin in Pakistan.   EastGate is considering dosing as many as 500 patients for inclusion in the Phase III clinical study.  The larger patient population gives the Company greater flexibility in dealing with submissions to surrounding territories for regulatory and marketing purposes.

  • GlobeNewswire

    Bill Abajian of EastGate Biotech Corp. to Speak at the 2019 M&A Forum for Pharma, Biotech, and Med Device to be Held Between August 12–14, 2019 in Philadelphia

    WEST CALDWELL, NJ and TORONTO, ON, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that Bill Abajian will be a Speaker at the upcoming 2019 M&A Forum for Pharma, Biotech and Med Device in Philadelphia, PA. The M&A Forum will take place between August 12–14, 2019.

  • GlobeNewswire

    EastGate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin, its Liquid Insulin Mouth Rinse for Type 2 Diabetes Patients

    WEST CALDWELL, NJ and TORONTO, ON, May 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today its plans to take the next steps to initiate Phase III  of its innovative liquid insulin mouth rinse solution, Insugin, for Type 2 diabetes patients in Pakistan. The Phase III study will be a multicenter, randomised, double-blind, placebo-controlled, parallel group study.  After appropriate screening, approximately 200 male and female patients from up to 10 study centers will be treated in this study.

  • GlobeNewswire

    EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes

    WEST CALDWELL, NJ and TORONTO, ON, April 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today positive Phase II Clinical Results of its innovative liquid insulin mouth rinse solution for Type 2 diabetes patients.

  • GlobeNewswire

    EastGate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply

    WEST CALDWELL, NJ and TORONTO, ON, March 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC PINK: ETBI),  a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, entered into a long term strategic alliance with MJ Biopharm (www.mjgroup.co.in) for the supply of human recombinant insulin.

  • GlobeNewswire

    EastGate Biotech Attends Arab Health Conference Seeking Additional Joint Venture Partnerships

    WEST CALDWELL, NJ and TORONTO, ON, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, is pleased to announce that key advisor William Abajian will represent the company at the Arab Health conference in Dubai. With more than 84,500 healthcare and trade professionals from 160 countries, EastGate Biotech will have the opportunity to visit 4,150 exhibiting companies from 66 countries whom are expected to convene at the Dubai World Trade Centre from 28th – 31st January 2019, for the 44th edition of the exhibition.

  • GlobeNewswire

    EastGate Biotech Appoints Additional Consultants in Preparation of Progressing Company Developments in 2019

    WEST CALDWELL, N.J. and TORONTO, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, appointed key consultants Saul A. Mashaal, PhmB, MBA and Munaf Ali, PhD to assist in regulatory matters and manufacturing of the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients.

  • ACCESSWIRE

    EastGate Biotech Appoints World-Renowned Diabetes Key Opinion Leader Dr. Lalit Upadhyay for Upcoming Initiatives

    WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / November 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, appointed key advisor Dr. Lalit Upadhyay to be the diabetes ambassador to help drive awareness of the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients. Dr. Lalit has devoted his life messaging that managing glucose levels in the body is the first line of defense against treating the deadly disease of diabetes.

  • ACCESSWIRE

    EastGate Biotech Receives Approval to Commence a Phase 2 Trial for Liquid Insulin Mouth Rinse Solution Addressing Patient Compliance in the Type 2 Diabetes Market

    3, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes mellitus (T2DM), today announced it received the approval from DRAP (www.dra.gov.pk) to commence a Phase 2 clinical trial of its oral mouth rinse. The generic name of the insulin mouth rinse is INSUGIN.